Haleon plc (NYSE:HLN) Shares Purchased by Mesirow Financial Investment Management Inc.

Mesirow Financial Investment Management Inc. increased its stake in shares of Haleon plc (NYSE:HLN) by 104.3% during the 4th quarter, HoldingsChannel.com reports. The fund owned 28,112 shares of the company’s stock after purchasing an additional 14,349 shares during the period. Mesirow Financial Investment Management Inc.’s holdings in Haleon were worth $268,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of HLN. FMR LLC increased its holdings in Haleon by 5.8% during the 3rd quarter. FMR LLC now owns 104,918,269 shares of the company’s stock worth $1,110,035,000 after purchasing an additional 5,768,117 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in Haleon during the 4th quarter worth approximately $42,193,000. Wellington Management Group LLP increased its holdings in Haleon by 49.9% during the 3rd quarter. Wellington Management Group LLP now owns 9,152,490 shares of the company’s stock worth $96,833,000 after purchasing an additional 3,046,841 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in Haleon by 25.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 5,084,202 shares of the company’s stock worth $53,791,000 after purchasing an additional 1,026,939 shares during the last quarter. Finally, Natixis Advisors LLC increased its holdings in Haleon by 142.5% during the 3rd quarter. Natixis Advisors LLC now owns 1,473,767 shares of the company’s stock worth $15,593,000 after purchasing an additional 866,070 shares during the last quarter. 6.67% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the company. HSBC restated a “hold” rating on shares of Haleon in a report on Wednesday, March 5th. Sanford C. Bernstein downgraded Haleon from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 8th. Hsbc Global Res downgraded Haleon from a “strong-buy” rating to a “hold” rating in a report on Wednesday, March 5th. Finally, Morgan Stanley downgraded Haleon from an “overweight” rating to an “equal weight” rating in a report on Friday, January 10th. Five analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.95.

Haleon Price Performance

Shares of NYSE HLN opened at $10.45 on Monday. Haleon plc has a twelve month low of $7.89 and a twelve month high of $10.80. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. The company has a market capitalization of $47.29 billion, a price-to-earnings ratio of 30.72, a price-to-earnings-growth ratio of 2.82 and a beta of 0.25. The business has a 50 day simple moving average of $9.68 and a 200-day simple moving average of $9.86.

Haleon (NYSE:HLN) last issued its quarterly earnings results on Thursday, February 27th. The company reported $0.05 earnings per share for the quarter. Haleon had a return on equity of 14.76% and a net margin of 10.85%. The business had revenue of $3.54 billion during the quarter, compared to the consensus estimate of $3.38 billion. As a group, equities research analysts expect that Haleon plc will post 0.43 earnings per share for the current year.

Haleon Increases Dividend

The business also recently disclosed a — dividend, which will be paid on Thursday, June 5th. Investors of record on Friday, April 25th will be given a dividend of $0.1166 per share. The ex-dividend date is Friday, April 25th. This represents a yield of 1.6%. This is a positive change from Haleon’s previous — dividend of $0.05. Haleon’s payout ratio is currently 58.97%.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.